Physician profile
Roberta L Anson
NPI 1154758175
$1,502.52
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $940 · 2023: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $305.86 | 2021-2023 | Zejula, Jemperli |
| Eisai INC. | $165.32 | 2022 | |
| Genmab U.S., INC. | $136.40 | 2022-2023 | Tivdak |
| Astrazeneca Pharmaceuticals LP | $119.49 | 2022 | |
| Seagen INC. | $91.21 | 2022 | |
| Incyte Corporation | $75.90 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $73.51 | 2022 | |
| Daiichi Sankyo INC. | $66.58 | 2021-2022 | |
| Blueprint Medicines Corporation | $45.76 | 2021-2022 | |
| Exelixis INC. | $45.10 | 2022 | |
| Mylan Institutional INC. | $43.59 | 2022 | |
| Genzyme Corporation | $41.96 | 2021 | |
| Gilead Sciences, INC. | $39.72 | 2021-2022 | |
| Clovis Oncology, INC. | $35.57 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $34.64 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $30.67 | 2022 | |
| Tersera Therapeutics LLC | $27.67 | 2021 | |
| Puma Biotechnology, INC. | $23.60 | 2021 | |
| Coherus Oncology, INC. | $22.18 | 2022 | |
| Genentech USA, INC. | $20.80 | 2022 | |
| Dendreon Pharmaceuticals LLC | $20.70 | 2021 | |
| G1 Therapeutics, INC. | $20.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Anson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.